From Wikipedia, the free encyclopedia
|
Combined Injectable Contraceptive
|
| Background |
| B.C. type |
Hormonal |
| First use |
about 1980 |
| Failure rates (first year) |
| Perfect use |
0-0.2[1]% |
| Typical use |
? |
| Usage |
| Duration effect |
1 month |
| User reminders |
? |
| Advantages and Disadvantages |
| STD protection |
No |
| Benefits |
Especially good if poor pill compliance. |
Combined injectable contraceptive (CIC) monthly injection of progesterone and estradiol taken to inhibit fertility. Brand names include Cyclofem, Novafem, Mesigyna, Lunelle.
[edit] History
- October 5, 2000, Pharmacia received FDA approval for Lunelle™ Monthly Contraceptive Injection.[1]
- April 2003, Pharmacia acquired by Pfizer (makers of Depo-provera).
- October 2003, Lunelle was discontinued in the U.S.
[edit] Use and packaging
Administered by intramuscular injection into the deltoid, gluteus maximus, or anterior thigh.[1] Ideally administered every 28 to 30 days, though demonstrated to be effective up to 33 days.[1]
[edit] Side-effects
The most prominent side effects are menstrual irregularities during the first 3 to 6 months of use.[1]
[edit] Formulations
- Lunelle contains medroxyprogesterone acetate (MPA) 25 mg plus estradiol cypionate (E2C) 5 mg.[1]
- Cyclofem contains depomedroxy-progesterone acetate (DMPA) 25 mg and estradiol cypionate 5 mg.
- Mesigyna contains norethisterone enanthate (NET EN) 50 mg and estradiol valerate 5 mg.
- Deladroxate contains dihydroxy-progesterone acetophenide 150 mg and estradiol enanthate 10 mg.
[edit] See also
[edit] Footnotes
